Is China A Black Swan For Big Pharma? (Part 1 of 2)

SHANGHAI - Spend a week in Shanghai these days and you hear a lot about how the Big Pharma model is broken. China's life sciences leaders - many of whom are returnees from the U.S. - are talking about this openly, much like industry leaders now do in the U.S. The difference is that many executives on the ground here believe that China is evolving into a laboratory for doing things differently, a catalyst for disruptive innovation that may propel the pharma industry into changing how it develops and delivers drugs

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip